Combination therapy group

DRUG3 trials

Sponsors

Miquel Pujol, Bin Cao, University of KwaZulu-Natal, Biomedical research ethics committee

Conditions

Methicillin Susceptible Staphylococcus Aureus SepticemiaMusculoskeletal Diseases OsteoarthritisPulmonary Mucormycosis

Phase 4

Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia

TerminatedNCT03959345

Miquel PujolMethicillin Susceptible Staphylococcus Aureus Septicemia

Start: 2019-05-31End: 2022-02-24Updated: 2022-04-21

Antifungal Drugs in Pulmonary Mucormycosis

Not yet recruitingNCT06756191

Bin CaoPulmonary Mucormycosis

Start: 2025-01-10End: 2026-12-31Target: 312Updated: 2025-01-01

Unknown Phase

Efficacy of physical agent in the management of osteoarthritis

Active, not recruitingPACTR201709002536342

University of KwaZulu-Natal, Biomedical research ethics committeeMusculoskeletal Diseases Osteoarthritis

Start: 2017-09-04Target: 120Updated: 2026-09-14

Related Papers

Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial.

2023-10-0227 citations

Multicentre, randomised, open-label, phase IV–III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible<i>Staphylococcus aureus</i>bacteraemia: study protocol for the SAFO trial

BMJ Open2021-08-015 citations